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SUMMARY
Ataxia-telangiectasia (A-T) is an autosomal recessive neurological
syndrome of considerable interest because homozygotes are highly
predisposed to cancer. Vigorous casefinding in the United States in
1970-72 and 1980-84 identified 231 white, 29 black, and three Oriental
A-T cases that provide information about the incidence and gene fre-
quency of A-T. White patients identified in this study were born at the
rate of 3.0 per million live births in the U.S. in the years 1965-69. The
highest observed incidence was in the state of Michigan for 1965-69,
where identified white A-T patients were born at the rate of 11.3 per
million births.
Based on the incidence data, the minimum frequency of a single
hypothetical A-T gene in the U.S. white population was estimated to
be .0017. Pedigree analysis, which estimates the gene frequency from
the proportion of affected close blood relatives of homozygous pro-
bands, estimated the most likely gene frequency to be .007 on the
assumption that A-T is a single homogeneous genetic syndrome, with
95% confidence limits of .0012-.02. Given that complementation anal-
ysis has demonstrated the genetic heterogeneity of A-T, the A-T
heterozygote frequency will probably fall between 0.68% and 7.7%,
with 2.8% being the most likely estimate.
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INTRODUCTION
Ataxia-telangiectasia (A-T) is a well-defined, fully penetrant autosomal reces-
sive syndrome in which the cardinal manifestations are progressive cerebellar
ataxia and oculocutaneous telangiectasia [1]. Although the neurological symp-
toms usually are noticed when the child begins to walk, it often takes several
years for their progressive nature and the telangiectasias to become evident.
While recurrent pulmonary infections, varied immune defects, and cancers all
occur at an unusually high frequency in A-T, many A-T patients survive until
adolescence or early adult life [2].
Cultured cells from A-T patients are unusually sensitive to cell killing by X-
or gamma-irradiation [3]. Such irradiation does not inhibit thymidine incorpora-
tion in A-T cells as it does in normal cells; complementation assays based on
this observation have detected at least five distinct A-T complementation
groups in the first 12 cell lines tested [4]. Clinical heterogeneity [5] in A-T has
not yet been correlated with this genetic heterogeneity.
Since A-T heterozygotes, who are relatively common in the population ac-
cording to the Hardy-Weinberg principle, may have a greater risk of cancer
than noncarriers [6], the A-T gene may play an important role in cancer
pathogenesis in the general population. The magnitude of the contribution of
the A-T gene to cancer incidence in the general population is a function of the
relative cancer risk associated with the gene and its frequency in the popula-
tion. However, only limited data have been available for estimating A-T gene
frequency [7], and newborn or population screening for A-T is not yet possible.
In the course of two epidemiological investigations of A-T families, we have
assembled a large and comprehensive sample of A-T patients from across the
U.S. This group of A-T patients enables us to estimate A-T gene frequency
using two independent approaches. First, the proportion of A-T children we
identified among all children born in a specific span of years provides a
minimum estimate of the incidence of A-T at birth. From this estimate, the
frequency of a hypothetical single A-T allele can be estimated from the Hardy-
Weinberg principle.
An alternative estimate can be derived from the incidence of A-T in nonsib-
ling relatives of the probands and the genetic structure of the families studied.
Homozygous close blood relatives of probands occur more frequently for rela-
tively common recessives like cystic fibrosis than they do for rarer syndromes.
Because of heterogeneity, either estimate is only a first approximation to the
composite gene frequency for all A-T alleles. These estimates can be improved
with information about the number of A-T loci and alleles and their relative
frequencies.
METHODS
Casefinding was carried out in 1970-72 and 1980-84 to identify A-T families in which
the health effects of the A-T gene in heterozygous carriers could be studied. The two
groups of A-T homozygotes identified during these surveys have been combined to form
the study population described here.
In the first casefinding period [6], referrals were sought from pediatric neurologists
and cerebral palsy centers in Pennsylvania, New Jersey, New York, and Massachusetts
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and from Dr. Elena Boder in Los Angeles, who, with Dr. Robert Sedgwick, first de-
scribed and named A-T and compiled a comprehensive register of patients in California
and some Western states. Forty white A-T patients from 26 nuclear families were
identified and included in the sample.
During the second period of casefinding (1980-84), our goal was to locate every re-
cent case of A-T in the U.S. As a first step, we identified all pediatric neurologists,
pediatric immunologists, and medical geneticists in the U.S. through their membership
in national professional societies and obtained a list of all United Cerebral Palsy (CP)
state and local affiliates. In 1980 and 1981, we wrote to these physicians and CP centers
and asked them to refer any A-T patients seen in the last 10 years for a comprehensive
study of A-T patients and their families. Nonresponders were written a second time and
again asked for their A-T patients. Many of the physicians and CP centers we wrote to
originally gave us the names of additional people to contact as potential sources of A-T
patients. We contacted a total of 1,315 physicians and CP centers in 49 states and the
District of Columbia seeking A-T patients. Three hundred fifty-one never responded to
our request, 732 replied that they had not seen any A-T patients, and the remaining 232,
from 42 states and the District of Columbia, told-us that they had seen A-T patients. The
Immunodeficiency Cancer Registry was also asked in 1982 to refer any of their A-T
patients, and several families volunteered to participate in our study after learning about
it through the National Ataxia Foundation or some other source.
From all these sources, we identified 399 new presumed cases of A-T and compiled as
much additional information as we could about each one. One hundred seventy-six of
these 399 A-T patients were not included in the study for the following reasons: the
patient or individual could not be located (65), the referring physician or we decided that
the patient did not meet our diagnostic criteria for A-T (62), the family or referring
physician refused to give consent for study (22), or the patient did not reside in the U.S.
or had died many years ago (27). The remaining 223 patients, many of whom were
referred to us by more than one source, were included in the study population.
To document A-T in each referred patient, we sought records of the diagnostic work-
up(s), as well as records for all hospitalizations and any published reports describing the
patient. We did not seek records for every visit a patient made to a physician. For all
deceased patients, we sought the death certificate and the autopsy report, if one had
been performed. For patients lacking information on serum AFP level [8], we offered to
perform this test, which many agreed to do. Full family pedigrees were constructed
whenever possible. The family's state of residence at the time of casefinding was re-
corded. Information about state of birth was obtained from the parents or the medical
records of each patient.
Living individuals met our diagnostic criteria for A-T if they had both progressive
ataxia and telangiectasia, unless the diagnosis was contradicted by clinical features that
were not consistent with the diagnosis. Deceased patients met our diagnostic criteria if
they had been diagnosed with A-T and we were able to obtain medical documentation
that supported the diagnosis. To be included in the sample, each nuclear family was
required to contain at least one proband who did meet the above criteria. Additional sibs
of probands who were described by their relatives as having A-T were accepted as such,
even though complete medical documentation was not available in all cases. Sixty
families contained multiple sibs with A-T who were included in analyses. In two addi-
tional families, second sibs, described by their parents as having A-T, were excluded
from all analyses since they had died overseas and no records could be recovered.
For the probands identified during the first casefinding period, ancestry information
based on the countries of birth of the grandparents and great-grandparents of the pro-
bands has been reported [9]. For the second group of families (1980-84), we obtained
information about foreign and American Indian ancestry of the grandparents of the
probands from the proband's parents in the white non-Amish families. The countries of
origin for common grandparents in consanguineous or related families in the sample
were counted only once.
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Pedigrees for 231 white patients contained in 138 nuclear families in 132 independent
kindreds were entered into a Data General Eclipse computer at the University of Utah
and prepared for analysis. The 50 A-T families that were not included in this analysis
were: the 23 nonwhite families, 23 white families for whom we did not have extended
pedigrees, and four Amish families whose small founding population renders their gene
frequency irrelevant to an estimate of the outbred U.S. Caucasian gene frequency.
Pedigree Analysis [10, 11] is a statistical method for the estimation of parameters of a
genetic model from observations collected on extended pedigrees. The statistical analy-
sis follows the method of maximum likelihood by calculating the probability of the set of
observations as a function of the parameters of the genetic model. Estimates of these
parameters are obtained by maximizing the likelihood function [12]. The computations
were made using the PEDIGREE ANALYSIS PACKAGE [13].
For this analysis, the observations consist of the disease status (affected or unaffected
with A-T) of each member of the pedigrees studied. The genetic model assumed is a
single recessive locus causing A-T. Information on A-T gene frequency is obtained from
these pedigrees by considering the frequency of affected individuals among the nonsib-
ling relatives. For example, for a common recessive gene, many first cousins would be
affected, yet for a rare recessive gene, many fewer first cousins would be affected. This
is because an affected cousin is most likely to have one gene in common with the
proband and, if his parents are not related, to have received one gene from the gene pool
at large. Thus, the frequency of the disease gene in affected cousins is a measure of its
frequency in the gene pool. We calculated the likelihood of the total set of observations
testing different values of gene frequency; that is, for each gene frequency considered,
we calculated the likelihood of having observed the specific pattern of affected cousins
that was found in the pedigrees studied.
Since these A-T families are not a random sample of the general population, we
needed to correct the likelihood of our observations to account for the fact that only
families containing one or more individuals affected with A-T are included in the calcu-
lation. This correction for ascertainment of the families was done by dividing the likeli-
hood described above by the probability of having observed a proband [11]. In most
families, the ascertainment event was one or more patients in a sibship. In one pedigree,
family A, ascertainment involved affected individuals in two nuclear families (fig. 1). If
Family A °T °° Family B
Family D Family C
ifO
* * A-T homozygote
= == = Undocumented consanguinity
Documented consanguinity




RACE AND SEX DISTRIBUTION OF THE 263 A-T PROBANDS
RACE
SEX White Black Oriental TOTAL
Male .......... 113 14 2 129
Female ........ 118 15 1 134
Total ........ 231 29 3 263
the parents of the proband are unrelated, the correction was for two independent genes
from the gene pool. However, if the parents of the proband are related, then both copies
of the A-T gene could have been inherited from a common ancestor. Therefore, we
included any known relationship between the parents in the ascertainment correction.
RESULTS
The sample contained 231 white patients from 165 different nuclear families,
29 blacks from 20 families, and three Orientals from three families (table 1).
There were nearly equal numbers of males and females in each racial group,
with a total of 129 males and 134 females. The number of affected individuals in
each sibship and the sibship size for the 163 families for whom complete sibship
information was available are given in table 2.
The 188 families resided in 38 different states; table 3 lists those states in
which five or more families lived. Over half of the families (52.1%) lived in the
following six states: California, Michigan, Pennsylvania, New York, Massa-
chusetts, and Texas, in which 37.3% of the U.S. population lived in 1970.
Ancestry information was known for 371 of the grandparents in the 135 white
COMPOSITION OF THE
TABLE 2
163 A-T PROBAND SIBSHIPS WITH COMPLETE INFORMATION
No. A-T PATIENTS IN EACH SIBSHIP
SIZE OF
SIBSHIP 1 2 3 4 TOTAL
1 ....... 24 ... ... ... 24
2 ....... 35 8 ... ... 43
3 ....... 19 15 1 ... 35
4 ....... 12 9 5 0 26
5 ....... 10 8 1 1 20
6 ....... 3 1 2 0 6
7 ....... 1 2 0 0 3
8 ....... 0 2 1 0 3
9 ........ 1 0 1 1 3
Total .... 105 45 11 2 163




STATES OF RESIDENCE FOR THE A-T FAMILIES
(STATES WITH FIVE OR MORE FAMILIES)
FAMILIES
Percent
STATE No. of total
California ............ 31 16.5
Michigan ............. 16 8.5
Pennsylvania ......... 16 8.5
New York ............ 14 7.4
Massachusetts ...... 1..11 5.9
Texas ................ 10 5.3
Illinois ............... 7 3.7
Maryland ............. 6 3.2
New Jersey ........... 6 3.2
Missouri ............. 6 3.2
North Carolina ........ 5 2.7
Oregon ............... 5 2.7
Total .............. 188 100.0
non-Amish families found during the 1980-84 casefinding period. The predomi-
nant regions of origin were Germany (13.3%), England and Wales (13.0%),
Ireland (12.9%), and eastern Europe, including Russia (12.7%), while only
2.3% were Italian. This pattern differed from that found among the cases
located during the first casefinding period [9], where 21.3% of the grandparents
with known ancestry had Irish ancestry, 18.8% Italian, 13.8% eastern Euro-
pean, and only 3.8% were of German origin.
Two hundred fifty-one A-T patients had been born in the U.S., 11 had been
born outside the U.S., and the location of birth was unknown for the remaining
patient. Peak years of birth for white A-T patients in the sample occurred in the
latter 1950s and the latter 1960s (table 4), when 2.5 and 3.0 probands were born
TABLE 4
CALENDAR YEARS AND PLACE OF BIRTH FOR THE 263 A-T PATIENTS
WHITES NONWHITES
YEARS Foreign or Foreign or
OF BIRTH U.S. unknown Total U.S. unknown Total
< 1950 ...... 23 0 23 0 0 0
1950-54 ..... 25 1 26 1 0 1
1955-59 ..... 45 1 46 2 1 3
1960-64 ..... 32 1 33 10 0 10
1965-69 ..... 45 3 48 6 0 6
1970-74 ..... 35 4 39 11 0 11
1975-84 ..... 16 0 16 0 1 1




No. WHITE A-T PATIENTS BY STATE AND CALENDAR YEAR OF BIRTH AND AS A
PROPORTION OF TOTAL WHITE LIVE BIRTHS
CALENDAR YEAR OF BIRTH
1955-1959 1965-1969
Patients Patients
per million per million
STATE OF BIRTH No. live births No. live births
Pennsylvania ......... 9 8.0 2 2.4
California ......... 6 3.9 2 1.3
New York ......... 5 3.2 4 3.1
New Jersey ......... 4 7.1 1 2.0
Texas ......... 3 2.8 4 4.4
Massachusetts ........ 2 3.6 3 6.6
Michigan ......... 2 2.2 8 11.3
Indiana ......... 0 ... 4 9.3
Missouri ......... 0 ... 3 9.2
All states ......... 45 2.5 45 3.0
NOTE: For states with three or more patients in at least one of the time periods.
in the U.S. per million white live births (table 5). The single year in which the
most white patients (12) were born in the U.S. was 1969, with 4.0 patient births
per million live births. Michigan had the highest observed birth incidence of
any individual state with 11.3 and 11.2 white patients born per million live
births for the periods 1965-69 and 1970-74. The peak birth years for nonwhite
A-T patients in the U.S. were 1970-74, with 3.6 patients born per million
nonwhite live births.
The sample included four published [14] Amish families related to each other
and with definite parental consanguinity; one set of parents were second
cousins, another set were third cousins, and the remaining two sets of parents
were more distantly related. In one black family, the parents of the proband
were half-siblings. The parents in two Iraqi families were consanguineous, first
cousins in one and second cousins in the other; there was an uncle-niece
marriage in a family from India; and a first-cousin marriage in a Dutch family.
Consanguinity in the remaining white families not belonging to genetically
isolated populations included one family each where the parents were first
cousins, first cousins once removed, and second cousins. There was one addi-
tional white family in which family members were certain that the parents of
the proband were second or third cousins, but the exact relationship could not
be documented (fig. 1, family C).
In addition to the four Amish families, 10 of the nuclear families of A-T
probands were related to each other (fig. 1). In one pair of families, sibling
probands in one family had a paternal aunt with A-T (family C). In two pairs of
families, probands were first cousins to each other (families B and D). Four
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GENE FREQUENCY
FIG. 2.-A-T gene frequency vs. log likelihood
Based on the proportion of A-T homozygous cousins of probands, the gene
frequency estimate for the compound A-T susceptibility allele under a fully
penetrant recessive model was .007 (fig. 2). The estimated 95% confidence
interval was from .002 to .020.
DISCUSSION
When the 5-year intervals of maximum U.S. birth incidence for white (1955-
59 and 1965-69) and nonwhite (1970-74) A-T patients in this study were exam-
ined, there was very little difference between the incidence of A-T in white and
nonwhite patients (2.5 and 3.0 vs. 3.6 A-T births per million). Overall, the most
common countries of origin for the ancestors of the A-T patients were: England
and Wales, Ireland, eastern Europe, and Germany. Italian ancestry was much
more common among the first group of A-T cases assembled (1970-72) than in
the most recent (1980-84) group. The A-T gene appears widely distributed in
European populations, but its relative frequency in different ethnic groups
cannot be estimated from our data.
The absolute minimum estimate for the A-T gene frequency can be derived
from the Hardy-Weinberg formula using as an estimate of the birth incidence
the observed proportion of A-T cases to all children born in the same time
period. Because the number of nonwhite patients is small, this analysis is
limited to the white A-T patients. The 5-year interval with the highest birth
incidence of A-T was 1965-69. This is not surprising, since patients born from
1965 to 1969 would have been old enough during the second and most extensive
casefinding period to have been diagnosed with A-T, yet young enough that
many would still have been alive and in contact with a potential referring
physician, or, if deceased, they would have died recently enough for the family
to be referred effectively for study. Based on the number of A-T patients born
in 1965-69, a minimum incidence rate of one case per 333,333 live births can be
estimated for the U.S. If there is a single A-T allele, its minimum frequency
estimate would be .0017, which is very close to the lower confidence limit
(.0012) for the gene frequency in the likelihood analysis. A frequency of .0017
corresponds to a heterozygote frequency of .0034 or one in 290 persons. Since
this estimate is based on the observed incidence of documented cases, it repre-
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sents the practical lower limit for estimates of A-T gene or heterozygote fre-
quency in the U.S. white population.
The estimate of .0017 for the minimum A-T gene frequency is likely to be
substantially less than the true gene frequency for two reasons. First, it is based
on the assumption that A-T is genetically homogeneous. However, there is
evidence for several different complementation groups in A-T [4]. If there are a
number of distinct genetic entities that comprise A-T, then the frequency of
heterozygous carriers of A-T genes is greater than would be estimated by the
Hardy-Weinberg principle assuming no genetic heterogeneity. Using the sim-
plifying assumption that there are N genetic entities of equal frequency that are
called A-T, then the composite gene frequency would be approximately the
square root of N times the gene frequency estimated on the assumption of a
single homogeneous genetic condition. Based on the incidence of A-T at birth
observed in this sample, the minimum gene frequency for A-T in the U.S. white
population would be .0034 if there are four equally frequent complementation
groups and .0051 if there are nine groups, with corresponding heterozygote
frequencies of .0068 and .010.
Further, the estimate of .0017 for the A-T gene frequency is inevitably low
because the cases identified by our surveys comprise an unknown fraction of all
A-T patients born in the United States. Since many A-T homozygotes are not
diagnosed until late in the first decade or early in the second decade of life, an
unknown proportion of affected individuals die before ever being diagnosed
with A-T. The pediatric neurologists, pediatric immunologists, and human ge-
neticists whom we surveyed probably had not seen all the diagnosed A-T
patients in the U.S. In addition, some physicians did not respond to our survey
or declined to refer their A-T patients for study and some referred A-T families
chose not to participate. Mudd et al. [15] compared the incidence of homocys-
tinuria as determined by metabolic testing at birth with that observed by
casefinding techniques similar to those used here in studying A-T and found
that almost fivefold more cases were found by newborn screening; the ob-
served incidence of A-T would have presumably been much higher if metabolic
screening for A-T at birth was possible and widely done.
Pedigree analysis, based on the finding that there were extended families that
contained related A-T homozygotes who were not all siblings yielded a gene
frequency estimate of .007, which corresponds to an incidence of approxi-
mately one A-T case in 20,400 births and a heterozygote frequency of one in 71
individuals. The highest observed incidence in our present study was the ap-
proximately one A-T case per 88,000 births observed in Michigan in 1965-69.
Our casefinding in Michigan for 1965-74 may have been more complete than in
other states or the incidence of A-T in Michigan may truly have been higher
than in other states.
From these data, what are the upper limits for estimates of the A-T gene
frequency? From pedigree analysis, a gene frequency of .02 was the upper 95%
confidence limit. If A-T in the U.S. white population consisted primarily of four
different complementation groups of approximately equal frequency, then the
maximum gene and heterozygote frequency estimates derived from the upper
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confidence limit from pedigree analysis would be .04 and .077, respectively.
Assuming that A-T is comprised of nine equally frequent complementation
groups would lead to an A-T composite gene frequency of .06 and a heterozy-
gote frequency of .113.
If the proportion of first-cousin marriages in the U.S. white general popula-
tion were known, the gene frequency could also be estimated through the
Dahlberg formula [16], since we know the proportion of first-cousin marriages
(1.8%) among all marriages producing white A-T patients in our sample. Al-
though the Dahlberg formula cannot be applied, this proportion of first-cousin
marriages is low compared to that observed in the U.S. in two other autosomal
recessive cancer-prone syndromes [17, 18] and is compatible with a relatively
high A-T gene frequency. The number of different complementation groups in
A-T and their relative frequencies are unknown. From the limited available
data [4], the "true" heterogeneity may be plausibly represented for estimation
purposes by four equally frequent complementation groups. On this assump-
tion, when it is possible to measure the A-T heterozygote frequency directly, it
will probably fall between 0.68%, based on the observed incidence, and 7.7%,
derived from the maximum gene frequency estimate from pedigree analysis,
with 2.8% being the most likely estimate based on pedigree analysis.
The proportion of A-T heterozygotes among all cancer patients or among
patients with a specific cancer can be estimated from the heterozygote fre-
quency and the relative risk of cancer for A-T heterozygotes. If the relative risk
for cancer at all sites in adults is two- or threefold [19], then A-T heterozygotes
would constitute about 5.4% or 8.0% of all adults with cancer. With an esti-
mated relative risk of six for breast cancer, about 15% of all breast patients
would be A-T heterozygotes. Although the maximum likelihood estimates of
gene frequency and cancer relative risk have wide confidence limits, these
estimates show that a substantial proportion of all cancer patients in the U.S.
may carry the A-T gene.
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